Technical Confirmation Process

Planning

• Collect list of people that will participate in the field test (Field Test Leader)
  • At least 3 sites are needed to get reasonable confirmation of results
  • If the profile covers multiple organs/cases, it is not necessarily required that each site test all cases as long as all cases get tested at multiple sites (e.g. 5 sites in total, each testing overlapping subsets of cases)
• Finalize comment form that will be used to collect results (RSNA Staff/Technical Committee)
  • One effective approach is to take the conformance checklists and add a column to indicate for each requirement if the site could do it and if they found it practical to do and if they have any comments

Soliciting Feedback

This step collects feedback on use of the document by implementers and users in the field, including clinical oncologists, imaging scientists, pharma, CRO’s, etc.

Whereas the review and public comment steps prior to this focused on the document itself, this step now seeks feedback on how well it works in practice. As such, comments are solicited specifically from those that have used it and only those that have used it.

A procedure is outlined below listing what is done (by whom).

Period: 30 days

• Announce Call for Feedback to mailing lists (RSNA Staff), including
  • link to the document
  • link to the QIBA Trial Implementation Feedback Template
• Email completed Feedback Template to Field Test leader (Commenters)
• Collate all Feedback comments into a Feedback Resolution spreadsheet (RSNA Staff/Field Test Leader)
  • <Currently some flexibility is allowed in the form of the document. Process Cmte is working on a more tuned template>
  • Document test coverage: were all requirements tested. If coverage is incomplete, consider dropping the requirement or document the rationale for finding it technically confirmed in the absence of testing.
• Additionally, summarize feedback into a report (Field Test Leader).
• Review comments, making changes to the document as needed (Technical Committee)
• Record comment resolutions in spreadsheet
• Vote on next step for the document (Technical Committee), either:
  • refer the document to the Modality Committee for Final Text publication
  • conduct another round of field test on revised document
  • place the document into inactive status
• Post Feedback Resolution spreadsheet, revised document to the Wiki (Field Test Leader/RSNA Staff)
• If profile requirements didn't change significantly, test sites may be able to claim conformance.

Feedback after Publication

The purpose of this process step is to actively seek and periodically respond to feedback on use of published documents. It is important to put this into context with other activities that may seem similar at first: Whereas the review and public comment steps that are part of the Drafting phase focus on the document itself, prior to its use, and the Collect Feedback step as part of the Field Test phase collects feedback on the initial use of the document given that it has been placed into trial implementation, this step is where longer-term, extended use of the document allows for actual assessment of its performance in practice. That is, over the course of time clinical trials may complete that had been designed with this, and/or other results from field usage may become evident either with the user or supplier base. As such, comments are solicited periodically for a wide range of the public that may connect with it in some way.

A procedure is outlined below listing what is done (by whom).

Period: 30 days

• Periodically, collect list of people that may have used the document and/or professional societies that may have a particular relationship to the document (RSNA Staff)
• Finalize comment form that will be used in the survey (RSNA Staff/Technical Committee)
• Send announcement to mailing lists (RSNA Staff)
  • reminder copy of document that has been placed into field test
  • provide a link to the QIBA User Feedback Template
• Email comments to RSNA Staff (Commenters)
  • commenters include full range of users of the document, e.g., vendors/suppliers, clinical oncologists, imaging scientists, pharma, CRO’s, etc. However, only people who have used document are included.
  • please use the provided comment form
• Collate all comments into a spreadsheet (RSNA Staff)
  • Summarize range of feedback to the questions into a report for review by the technical committee provided by RSNA Staff.
  • Technical Committee decides what changes to make (if any) to the document and whether to refer it to the Modality Committee for re-publication of an updated version, whether to branch the document leaving the current version in place but spawning a derivative, or to retire the document
• Record resolution in spreadsheet
  • Regardless of recommended status for this document, ensure that the results are made available to related activities